Sevelamer Carbonate In vitro binding study for EMA submission [Regulatives / Guidelines]

posted by jansari – India, 2022-05-26 19:59 (41 d 23:00 ago) – Posting: # 23025
Views: 205

Dear divyen,

Thank you very much for providing this supporting documents to justify the query..bt this PAR published in the year 2014 and 2017..so my concern is that whether we have to justify the response with this reference docs?

As EU release one guidance documents for locally acting drug in GI tract in oct 2018.this guidance is not as much clear as us fda guidance..

but in this guidance on page no. 10 stated that in vitro similarity should be assessed with +-10%acceptance limit..so similarity should be proven based on T/R ratio or 90%CI needs to b calculate?

Reference doc's attached with this post..


Kindly guide on this...

Thnk you in advance.....


Edit: Send by email to the forum address. @Jansari: Reply directly in the forum in the future. THX. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,193 posts in 4,651 threads, 1,574 registered users;
online 13 (1 registered, 12 guests [including 4 identified bots]).
Forum time: Thursday 19:00 CEST (Europe/Vienna)

Any sufficiently advanced technology
is indistinguishable from magic.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5